Valeant Pharmaceuticals International News

The parent company of DPT Laboratories has agreed to sell its dermatology division, Coria Laboratories Ltd., to Valeant Pharmaceuticals International for $95 million.

This transaction significantly expands Valeant's business in the U.S. and enhances the company's dermatology franchise through the acquisition of key products which complement its current portfolio.

GlaxoSmithKline and Valeant Pharmaceuticals International recently announced that they have entered into an exclusive worldwide collaboration agreement for the investigational drug retigabine, a first in class ...

Valeant Pharmaceuticals International and GlaxoSmithKline have entered into an exclusive worldwide collaboration agreement for the investigational drug retigabine, a first in class neuronal potassium channel ...

Valeant Pharmaceuticals International has entered a collaboration agreement with GlaxoSmithKline for the investigational drug retigabine, a neuronal potassium channel opener for treatment of adult epilepsy ...

Company founder and former CEO, Michael A. Griffith has resigned in order to follow other possibilities.

GlaxoSmithKline Signs Deal Worth Up to $820 Million with Valeant Pharmaceuticals International 8/28/2008 ALISO VIEJO, Calif.

Aptuit Inc. , a Greenwich, Conn.-based drug-development services firm, has appointed Timothy C. Tyson as executive chairman and acting CEO, company officials said.

Valeant Pharmaceuticals International today announced that members of its senior management team will make a presentation at the UBS Global Life Sciences Conference on Wednesday, September 24, 2008 at 11:00 ...

Lower sales and higher taxes pushed Valeant Pharmaceuticals International to a loss for the second quarter, the company said Monday.

Aug. 11, 2008 - Valeant Pharmaceuticals International today announced second quarter financial results for 2008.

The joint ventures will be majority owned by Meda and Valeant will own a minority interest.

As part of an ongoing effort to streamline and focus its operations, Valeant Pharmaceuticals International sold its Western and Eastern European businesses to specialty pharma company Meda AB for $392 million ...

Under the terms of the agreement, Meda will pay $392 million in cash for the Valeant subsidiaries in those markets, and the rights to all products and licenses currently marketed by Valeant in the divested ...

The recovery rating change stems from the company's notice of full redemption of the $300 million in 7% senior notes which is deemed senior to the convertible subordinated notes, said Standard & Poor's credit ...

The executive vice president and chief administrative officer of Valeant Pharmaceuticals International, a specialty pharmaceutical company, bought 2,049 shares of common stock, according to a Securities and ...

MBIA Inc. issued the following statement in response to questions concerning the impact of Moody's Investors Service's downgrade of MBIA Insurance - PHILADELPHIA-- --Sunoco, Inc.

ALISO VIEJO, Calif. - Valeant Pharmaceuticals International today announced that it will redeem all of the $300 million aggregate principal amount outstanding of its 7% Senior Notes due 2011 .

Valeant Pharmaceuticals International said Thursday that its mid-stage hepatitis C candidate taribavirin could replace a drug used in a common treatment regimen.

Companies Featured in This Article: Wells Fargo, Jarden, Valeant Pharmaceuticals International, Allied Capital, Marathon Acquisition, Mobile Mini, Unitrin, Ram Holdings, BGC Partners, UCBH Holdings, Capital ...